New Data Offers Insights Into The Potential Role For Tykerb(R) / Tyverb(R) (Lapatinib
GlaxoSmithKline announced the results of three studies evaluating lapatinib - an oral, small molecule inhibitor of HER2 - in various breast cancer settings, either in combination with other targeted therapies or as a monotherapy. Use of lapatinib in these settings is investigational. Results from these studies are being presented during the annual American Society of Clinical Oncology (ASCO) meeting in Chicago, May 30 - June 3, 2008.
More... |
All times are GMT -7. The time now is 12:52 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021